<code id='66FB9DDCC9'></code><style id='66FB9DDCC9'></style>
      • <acronym id='66FB9DDCC9'></acronym>
      <center id='66FB9DDCC9'><center id='66FB9DDCC9'><tfoot id='66FB9DDCC9'></tfoot></center><abbr id='66FB9DDCC9'><dir id='66FB9DDCC9'><tfoot id='66FB9DDCC9'></tfoot><noframes id='66FB9DDCC9'>
      • <optgroup id='66FB9DDCC9'><strike id='66FB9DDCC9'><sup id='66FB9DDCC9'></sup></strike><code id='66FB9DDCC9'></code></optgroup>
        5. <b id='66FB9DDCC9'><label id='66FB9DDCC9'><select id='66FB9DDCC9'><dt id='66FB9DDCC9'><span id='66FB9DDCC9'></span></dt></select></label></b><u id='66FB9DDCC9'></u>
          <i id='66FB9DDCC9'><strike id='66FB9DDCC9'><tt id='66FB9DDCC9'><pre id='66FB9DDCC9'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / comprehensive / fashion      
           
     
           
      
          fashion 
           
      
           
      
           
       2025-10-06 19:09:31 
   
      
           
      
           
                        
          fashion  
          
                                   
                 
                                      author：Wikipedia   
                                        
                                      
                                      Page View：786
                                  
                                    
          
                                   
          Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT
          Darron Cummings/AP
          A couple billion here, a couple billion there, and pretty soon Eli Lilly hopes it will be talking about real money.
          Eli Lilly agreed to purchase Point Biopharma Tuesday morning for $1.4 billion, a 90% premium, adding to its pipeline of cancer drugs. Point is developing cancer drugs that deliver a focused dose of radiation to tumor cells. Data for its lead medicine, for prostate cancer, are expected in the fourth quarter. It is also developing a drug for neuroendocrine tumors.
          advertisement
          Point operates a 180,000-square-foot radiopharmaceutical manufacturing facility in Indianapolis, and a radiopharmaceutical research and development center in Toronto.
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe													Log In											
                      
                              
          
                                 Previous article：

                                
                                          At least 12 people were injured in a blast at a port in northwest Turkey
                                
                            
          Next article：  
                                      
                                          Malaria cases in Florida and Texas: Here’s what you need to know
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles